MAGEC2 Antibody

1. HCA587/MAGEC2 directly binds TAF9 via its CR domain, suggesting that HCA587/MAGEC2 may involve in TAF9 binding with DNA to regulate certain genes transcription. PMID: 29257297
2. our findings revealed a previously unrecognized regulation of STAT3 activation in tumor cells by cancer/testis antigen MAGEC2, and provided a molecular mechanism for the oncogenic activity of MAGEC2 in cancer cells. PMID: 27775077
3. High MAGE-C2 expression was found in 38.18% of triple negative breast cancer tissues and in 9.09% of adjacent tissues. High MAGE-C2 expression in TNBC patients was closely associated with tumor node metastasis and shorter survival time. PMID: 27843173
4. our study provides a suitable cell model for exploring the biological functions of MAGEC2 in malignant cells, and sheds light on the molecular pathway by which MAGEC2 promotes tumor development. PMID: 27636589
5. The expressions of MAGE-C2 mRNA and MAGE-C2 protein were closely associated with stage, metastasis of lung cancer. PMID: 26903162
6. In gastrointestinal stromal tumors, 5/51 (10%) patients expressed MAGE-C2. High-grade GIST are more likely to express MAGE-C2. MAGE-C2 also significantly correlates with mitotic rate and tumor size. PMID: 24713551
7. Our results indicate that MAGEC2 has a role in breast cancer metastasis through inducing epithelial-mesenchymal transition PMID: 24687377
8. overexpression of HCA587 resulted in a significant enhancement of LMP1-induced IL-6 production. These data indicate that HCA587 is a new negative regulator of BS69 PMID: 24866244
9. MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. PMID: 23096706
10. Cytotoxic T cell clones directed against MAGE-C2 peptides recognize EB81-melanoma tumor cells treated with interferon (IotaFN)-gamma. PMID: 22925930
11. MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. PMID: 21754986
12. MAGEC2 is a sensitive and novel marker for seminoma. PMID: 21780320
13. p43-57 is the first HCA587-derived major histocompatibility complex class II-restricted epitope to fulfil all prerequisites for use as a peptide vaccine in patients with HCA587-expressing tumors PMID: 21595801
14. HCA 587 may be a valuable target antigen for diagnosis and vaccination of hepatocelular carcinoma patients. PMID: 12920247
15. identified 2 antigens encoded by gene MAGE-C2 which are recognized by several melanoma-specific cytolytic T lymphocyte clones isolated from a melanoma patient; both antigens are presented by HLA-A2 PMID: 14999777
16. CT10 expression was more frequently found in squamous cell carcinoma than in adenocarcinoma. PMID: 15061963
17. because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific PMID: 17096150
18. the MAGE-A3 and MAGE-C2 gene promoter regions are de-methylated in the presence of activated KIT but become methylated on inhibition of KIT, consistent with the downregulation of mRNA and protein PMID: 17495964
19. MAGE-C2/CT-10 is expressed in hepatocellular carcinoma PMID: 18942708

Show More

Hide All

HGNC: 13574

OMIM: 300468

KEGG: hsa:51438

STRING: 9606.ENSP00000354660

UniGene: Hs.123536